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Abstract 
Vanadate, one of the most relevant forms of vanadium in 
solution, has been associated with the regulation of 
various enzyme activities (e.g. phosphatases, 
ribonucleases, ATPases, etc.) and shown to exhibit 
important biological effects. Several in vivo and in vitro 
studies have clearly demonstrated that any deficiency or 
excess of vanadium can seriously affect bone formation 
and its metabolism. Bone-related effects result largely 
from vanadium insulino-mimetic capabilities mediated by 
specific inhibition of protein tyrosine phosphatases 
(PTPases) and consequent activation of tyrosine kinase 
receptors (e.g. insulin receptor). Although mammals have 
been repetitively shown to be appropriate models to study 
vanadate mechanisms of action, fish have recently 
emerged as alternative models. Fish has been recognized 
as suitable model to study vertebrate bone formation and 
the natural presence of high quantities of vanadium in 
water makes it even more suitable to investigate vanadium 
effect on bone formation. Recent data obtained using fish 
bone-derived cells revealed that micromolar 
concentrations (5 µM) of monomeric and decameric 
vanadate slightly stimulate growth performances while 
strongly inhibiting extracellular matrix mineralization 
through mechanisms involving both alkaline phosphatase 
and MAPK pathways. Recent data obtained in fish cells 
will be discussed here and further compared to results 
obtained in mammalian systems. 
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1. INTRODUCTION 
 
Vanadium is a trace element that has been shown to be essential for biological 
activity in various organisms [1-3]. In plants and algae, vanadium is directly involved in 
enzyme activity, acting as a cofactor in vanadium nitrogenases and vanadate-dependent 
haloperoxidases. In mammals, reduced doses of vanadium have been associated with 
poorly developed animals and higher rates of spontaneous abortion or mortality [4]. 
Biological effects of vanadium in vertebrates, in particular in mammals, 
essentially come from its capacity to interfere with several key enzymes, such as 
ATPases, phosphorylases, phosphatases (alkaline, acid and protein phosphatases) and 
ribonucleases [2]. This interference has been attributed to vanadium oxidation states VV 
and VIV (vanadate and vanadyl, respectively), which exhibit some analogy with 
phosphate, although to different extents (strong for vanadate and weak for vanadyl). 
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Inhibition of phosphatases by vanadate was attributed to the formation of good 
transition state analogues during enzymatic catalysis [2,5] and a similar mechanism was 
proposed for vanadyl although its geometry of coordination is somewhat different to 
that of phosphate [2]. 
An important feature of vanadate resides in its capacity to promote distinct 
effects depending on its oligomerization (monomeric to decameric species according to 
pH and concentration [6]) as shown using in vitro and in vivo models [7-9]. For 
example, decameric species were shown, in fish, to induce higher oxidative stress, 
haemoglobin oxidation, stimulate antioxidant enzyme activities and generate more 
tissue damages than other oligomeric species [10-12], while monomeric species 
apparently accumulated at higher rates and doses in cardiac muscle, red blood cells and 
plasma [13]. Aspects related with decavanadate in vivo effects are been reviewed in 
Chapter 9 of this book. Decameric species also revealed stronger inhibition and affinity 
for ATPases, in particular myosin ATPase and sarcoplasmic reticulum (SR) Ca2+- 
ATPase [9,14-16]. Decavanadate effects in the contractile system and in SR calcium 
pump are being reviewed in Chapters 5 and 7 of this book, respectively. 
The most important biological effect of vanadium is probably insulin mimicking. 
It was first demonstrated in the early 80’s, when vanadate and vanadyl treatments 
applied to isolated rat adipocytes [17,18] were shown to stimulate hexose transport, 
glucose oxidation and lipogenesis, as insulin [19]. Additional in vivo studies showed 
that oral administration of vanadate to streptozocin-treated diabetic rats (STZ rats) 
resulted in decreased blood glucose to normal levels [20,21], confirming its action as a 
substitute of insulin. Vanadate was consequently proposed as a possible therapeutic 
agent for diabetes mellitus (insulino-dependent). However, the therapeutic use of 
vanadate has been seriously hampered by its relatively high toxicity [22,23]. Recent 
efforts have therefore focused on the discovery of chelators, which would reduce 
vanadyl and vanadate toxicity while preserving its insulino-mimetic properties [24]. 
Insulino-mimetic properties of vanadium have been associated to specific 
inhibition of protein tyrosine phosphatases (PTPases) and consequent activation of 
receptor-associated protein tyrosine kinase (PTK), including that of insulin receptor 
[23,25,26]. Alternatively, non-receptor PTK, e.g. insulin receptor substrate 1 (IRS-1), or 
cytosolic PTK can be activated [27]. Two pathways involved in vanadate intracellular 
signalling have been identified, both resulting in distinct effects (Figure 1). A common 
feature of both pathways is the activation of PTK domain in IRS-1 through 
phosphorylation of tyrosines. While metabolic effects are mediated by 
phosphatidylinositol-3 kinase (PI-3K) activation, effects on cell proliferation and 
differentiation result from the activation of mitogen-responsive protein kinases 
(MAPK) [28]. Alternatively, specific insulin-like effects, e.g. glycogen synthase 
activation, have been associated to PI-3K/Ras/ERK activation [27]. 
While most studies investigating vanadium effects have been done in adipose 
tissue, bone has recently emerged as a system of interest after its regulation by insulin 
and IGF1 was demonstrated [1,29-31] and after vanadium was shown to accumulate in 
mammalian bones [32] and affect bone formation when absent from diet [4,33]. 
Accumulation of vanadium within bone, was first proposed to be related to a 
detoxification process [34,35]. Severe malformations occurring in bone of animals 
lacking vanadium however suggested that it could interact with specific growth factor-
dependent signalling, in particular those known to control bone development: platelet-
derived growth factor (PDGF), fibroblast growth factors (FGF1 and 2), insulin, insulin-
like growth factors (IGF1 and 2), transforming growth factors beta (TGF-β1, 2 and 3), 
and bone morphogenetic proteins (BMP) [30,36]. Because insulin, IGFs and TGF-β 
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bind to specific tyrosine kinase receptors and are involved in osteoblast differentiation, 
they have been therefore considered as putative targets for vanadium. Effects due to 
insulin and IGF mimicking action of vanadium, were first demonstrated in vitro by 
Canalis and colleagues, who showed that concentrations below 15 µM of sodium 
vanadate increased DNA synthesis and mitotic index of rat calvaria primary cultures 
[31]. Since then, two mammalian cell lines, MC3T3-E1 (developed from newborn 
mouse calvaria, composed of pre-osteoblasts and able to mineralize extracellular matrix 
(ECM) [37]) and UMR106 (developed from rat osteosarcoma, composed of 
differentiated osteoblasts and unable to mineralize the ECM [38]) were shown to be 
particularly useful in understanding vanadium effects in bone insulin and IGF 
mimicking effects in bone and important features like tyrosine kinase receptors 
phosphorylation (with consequent activation) and activation of signalling mechanisms 
have been characterized [39].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.  Insulin signalling pathways and putative regulation by vanadium. Ins indicates insulin peptide; 
V indicates vanadium; α and β represent the subunits of insulin tyrosine kinase receptor; circled P 
represents phosphorylation of tyrosines in PTK domain within the β subunit of insulin receptor; PKB 
indicates protein kinase B, the activated intermediate in PI-3K pathway. GRB-2, Ras, MEK and ERK 
indicate intermediate adaptor proteins in MAPK pathways. 
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Until recently, effects of vanadate on bone metabolism have been exclusively 
characterized in vitro using these two mammalian bone-derived cell lines [39]. The 
recent contribution of a fish-bone derived cell line to this characterization is hereby 
described and results obtained compared to those derived from studies on mammalian 
cell lines and its suitability as an in vitro model system to study these effects is further 
discussed. 
 
2. MAMMALIAN CELL LINES AS IN VITRO MODELS TO STUDY 
VANADIUM MECHANISMS OF ACTION IN BONE 
 
Primary cultured cells from rat and chicken calvaria were the first in vitro 
systems used to investigate vanadium insulin-like effects in bone [31,40] and have 
contributed to the characterization of osteogenic action of vanadium in mammals 
including the inhibition of alkaline phosphatase (ALP) activity and the stimulation of 
type-I collagen synthesis [39], two mechanisms essential to the correct mineralization of 
the extracellular matrix (ECM) of bone cells [41]. Osteogenic actions of vanadate are 
being reviewed in Chapter 13 of this book. The key role of growth factors, e.g. IGF1, 
and tyrosine protein phosphorylation in the mediation of vanadium action was later 
demonstrated using mouse MC3T3-E1 and rat UMR106 cell lines [39]. Osteoblastic 
differentiation of these cells, monitored through the measurement of ALP activity, was 
show to be inhibited by vanadate, vanadyl, hydroperoxo- and peroxo-vanadium, in 
agreement with previous observations in primary bone-derived cultures [42]. 
Interestingly, enzymatic activity of PTPases was show to be inhibited in treated cells, 
suggesting a probable signalling interference with insulin and other growth factors that 
bind to tyrosine kinase receptors. In more recent experiments, vanadate, vanadyl and 
pervanadate were shown to stimulate cell proliferation at low doses, while higher doses 
severely arrested growth [43]. Primitive vanadium complexes (vanadium oxalate, 
citrate, tartrate and nitrilotriacetate) tested in mammalian MC3T3-E1 and UMR106 
bone-derived cell lines revealed effects similar to those of vanadate: stimulation of cell 
proliferation, glucose consumption and protein content. It is worth to note that both 
vanadate and vanadium nitriloacetate exhibited a stronger inhibition of UMR106 cells 
differentiation [44]. However, complex toxicity was still high. 
The new generation of vanadium complexes (e.g. 
bis(maltolato)oxovanadium(IV) - BMOV - and bis(maltolato)dioxovanadium(V) - 
BMV) also exhibited effects similar to those of vanadium but revealed lower toxicity 
rates (BMV). All treatments with these complexes promoted cell growth in a biphasic 
manner, as well as increased phosphorylation of tyrosine residues, consistent with 
previous observation of strong inhibition of PTPases. In addition, BMOV, like 
vanadate, strongly inhibited ALP activity [45,46]. Similar results have been observed 
when using vanadyl/aspirin complex [47,48]. Relevant information concerning 
vanadium regulatory mechanisms associated to insulin signalling pathways were 
obtained only recently. Involvement of MAPK and PI-3K pathways in vanadium 
osteogenic effects was investigated using two complexes, trehalose vanadyl (TreVO) 
and vanadyl ascorbate (VOAsc) [49,50] and specific inhibitors of these pathways. 
While stimulation of cell proliferation and type-I collagen synthesis were shown to be 
mediated by an insulin-dependent mechanism, stimulation of glucose consumption and 
inhibition of ALP activity were apparently mediated by an insulin-independent 
mechanism. Another important observation was the increased phosphorylation of key 
intermediates of these cascades upon vanadium treatments. One of the major 
subfamilies of the MAP kinases, the extracellular signal-regulated kinase (ERK), has 
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been shown to be phosphorylated / activated in UMR106 and MC3T3-E1 cells after 
vanadium treatments. This effect is apparently mediate by a PI-3K/ras/ERK 
(extracellular signal-regulated kinase) pathway [39]. This mechanism is probably 
essential to explain vanadium effect in bone and will be further discussed. 
 Although vanadium insulin-dependent and insulin-independent actions have 
been already described in mammalian bone-derived in vitro systems, there is a lack of 
information concerning other vertebrate bone-derived systems, in particular those 
derived from marine vertebrate species. 
 
3. TELEOST FISH BONE-DERIVED CELL LINES AS AN ALTERNATIVE TO 
MAMMALIAN SYSTEMS TO STUDY VANADIUM EFFECTS IN BONE 
 
VSa13 bone-derived cell line has been recently developed from the vertebra of 
Sparus aurata, a marine teleost fish, and fully characterized [51]. This cell line is 
capable of mineralizing its extracellular matrix under appropriate culture conditions and 
has been associated to the chondrocyte lineage as suggested by a relatively high 
expression of matrix gla protein (a calcification inhibitor normally produced by 
chondrocytes in cartilage), no expression of osteocalcin (an osteoblastic marker) and 
strong alcian blue staining (normally associated with cartilage extracellular matrix). The 
suitability of VSa13 cells to study in vitro vanadium insulin-like action on bone was 
confirmed by its responsiveness to insulin treatments (10 nM insulin was shown to 
decrease by 25% the degree of extracellular matrix (ECM) mineralization in VSa13 cell 
[52]). To date, only vanadate oligomeric solutions have been tested in VSa13 cells. 
Metavanadate (containing n-meric species with n = 1-5) and decavanadate (n = 1 or 10) 
effects on VSa13 cells viability, growth, accumulation and ECM mineralization have 
been investigated [52]. Vanadate oligomerization did not originate differences in 
toxicity levels after prolonged exposures (metavanadate and decavanadate solutions 
were shown to be non-toxic at concentrations below 10 µM during 15 days). However, 
decameric species exhibited higher toxicity after 2 h of treatment using 1 mM 
concentration (acute toxicity). Similarly, accumulation of vanadium in VSa13 cells was 
oligomerization-independent from 4 to 24 h but much slower for decavanadate within 
the first 2 h of treatment. These results were shown to be coherent with decameric 
species decomposition rate into monomeric species (half-life time of approximately 
150 min), suggesting that decavanadate long-term effects resulted mainly from 
monomeric species. However, in short-term treatments in which decameric species were 
still present in solution, vanadate was shown to accumulate much slower in cells, and to 
induce higher toxicities. These results reinforced the hypothesis of the higher toxicity of 
species highly oligomerized, which are probably formed in specific cellular 
environments (e.g. in which the pH is low). Merged results of long-term treatments by 
monomeric and decameric vanadate indicate that cell proliferation was stimulated 
(Figure 2) in a dose-dependent manner. The observation that insulin did not stimulate 
VSa13 cell proliferation (inset of Figure 2) suggested that mitogenic pathways may not 
be controlled by this hormone in these cells. It also suggested that vanadate effects on 
cell proliferation were not mediated through insulin signalling pathways, and possibly 
involving other PTK. 
However, mineralization of VSa13 ECM was later show to be negatively 
regulated by insulin [52] (Figure 3), demonstrating the presence of insulin receptors and 
signalling pathways in these cells. ECM mineralization was also inhibited by vanadate 
in VSa13 cells, and combined treatments with insulin and vanadate resulted in stronger 
inhibition (31%, 76% and 87% inhibition in cells treated with insulin, vanadate and 
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insulin + vanadate, respectively; Figure 3). Effect of vanadium on extracellular matrix 
(ECM) mineralization in mammals has been reported in a recent study [50]. 
Surprisingly, vanadyl(IV)-ascorbate complex strongly increased mineral deposition 
within ECM of MC3T3-E1 (up to 20-fold using concentrations from 5 to 25 µM). This 
result, at the opposite of that observed in fish bone-derived cells, was even more 
surprising considering the mild effects of vanadium on bone markers: ALP activity was 
maintained or slightly decreased and type-I collagen synthesis was only slightly 
increased (approximately 10%). The opposite effect of vanadium on extracellular matrix 
(ECM) mineralization observed in VSa13 and MC3T3-E1 cells may be related to the 
species studied (fish versus mammal) or the cell types used (osteoblast versus 
chondrocyte) and will require additional studies in the future. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Vanadate and insulin effects on VSa13 cell proliferation. VSa13 cells were seeded in 96-well 
plates at 1.5×103 cell/well then treated with metavanadate and decavanadate using concentrations ranging 
from 2.5 to 7.5 µM. Cell viability was evaluated at appropriate times using MTS assay. Inset indicates 
vanadate (5 µM) effect on VSa13 cell proliferation compared with that of insulin (10 nM) after 12 days of 
treatment. Vanadate values are the mean of metavanadate and decavanadate merged data resulting from at 
least six independent experiments. Insulin values are the mean of at least 3 independent experiments. 
 
Data obtained from VSa13 cells suggested that vanadate effect on ECM 
mineralization probably involve insulin-signalling pathways, but the contribution of 
other mechanisms must also be considered. In that aspect, preliminary data obtained in 
VSa13 cells indicated a strong decrease in ALP activity in vanadate-treated cells during 
ECM mineralization (Figure 4; our unpublished results). ALP activity in VSa13 cells 
was demonstrated to be up regulated during ECM mineralization [51], which is 
consistent with a differentiation process, but treatments with 5 µM monomeric vanadate 
have shown to massively decrease this activity. Specific inhibitors should be tested, in 
order to evaluate to what extent, and which insulin signalling pathways are mediating 
vanadate inhibition of ECM mineralization. Preliminary data from experiments using 
MAPK and PI-3K inhibitors (PD98059 and wortmannin, respectively) have involved 
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mitogenic pathways (possibly through PI-3K/ras/MAPK signalling pathways). This 
issue will be further discussed in the next section of this chapter. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Effect of vanadate and insulin on VSa13 extracellular matrix (ECM) mineralization. Mineral 
deposition was revealed by von Kossa staining and evaluated by densitometric analysis. Values are the 
mean of metavanadate and decavanadate merged data resulting from at least six independent experiments. 
Asterisks indicate statistically significant differences compared to control (or between conditions) 
according to Student’s test (* p < 0.05, *** p < 0.001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Effect of vanadate and insulin on alkaline phosphatase (ALP) activity of VSa13 cells during 
extracellular matrix (ECM) mineralization. Extracts from ECM mineralized cells alternatively treated 
with either insulin alone or metavanadate alone, or both, were collected in 0,1% (v/v) Triton X-100; 
samples ALP activity was evaluated in 50 mM glycine plus 0.5 mM MgCl2 reaction buffer using 0.5 mM 
pNP-P (p-nitrophenyl-phosphate) as substrate. Values are the mean of at least three independent 
experiments. Asterisks indicate statistically significant differences compared to control according to 
Student’s test (* p < 0.05, ** p < 0.01). 
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4. MECHANISMS OF ACTION OF VANADIUM IN BONE-DERIVED CELL 
LINES 
 
 Different in vitro systems (different species and cell type) have been used to 
investigate proliferative and mineralogenic effects of vanadium. Available data 
(summarized in Table 1) suggest that vanadium may promote distinct effects depending 
on the system used. Although similar toxic and proliferative effects have been 
recognized in both systems (i.e. mammalian and fish), effects on ECM mineralization 
were contradictory (i.e. stimulation in mammalian cells and inhibition in fish cells). 
Interestingly, vanadium-treated MC3T3-E1 cells exhibited increased ERK 
phosphorylation. ERK activation by vanadium salts was previously demonstrated in 
experiments using Chinese hamster ovary cells overexpressing insulin receptor [27]. 
Stimulation of ras/ERK pathway mediated by PI-3K activation (resulting in the 
PI-3K/ras/ERK pathway) promoted important insulino-mimetic effects, e.g. glycogen 
synthesis and glucose homeostasis. Nevertheless, this pathway is commonly associated 
to growth promotion effects [53]. Recently, the ECM mineralization of MC3T3-E1 cells 
was show to be significantly inhibited by PDGF, also through the activation of ERK 
pathway. This result is, on one hand, in contradiction with the ERK-dependent 
mineralogenic effect of vanadium in MC3T3-E1, but, on the other hand, in total 
agreement with the anti-mineralogenic effect of vanadium in VSa13. It also suggests 
that vanadium effect could be mediated in VSa13 through ERK/MAPK pathway, an 
hypothesis which is strengthened by preliminary data showing the reversion of 
vanadium effect on cell proliferation by PD98059, a specific inhibitor of MAPK 
pathway early events (Figure 5; our unpublished results). However, increased ERK 
phosphorylation in VSa13 cells is still to be confirmed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Effect of MAPK and PI-3K inhibitors on vanadate stimulation of VSa13 cells proliferation. 
VSa13 cells were seeded in 96-well plates at 1.5×103 cell/well then treated with 7.5 µM metavanadate 
Cell viability was evaluated at 8 days using MTS assay. Values are the mean of at least three independent 
experiments. Asterisks indicate statistically significant differences compared to control according to 
Student’s test (* p < 0.05, ** p < 0.01). 
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Alkaline phosphatase (ALP) activity (and cell differentiation) was show to be 
similarly affected by vanadium in all systems. Preliminary data suggest that vanadate 
may not directly inhibit ALP activity in VSa13 cells (our unpublished result). We 
hypothesize that vanadate may affect indirectly the levels of ALP activity during ECM 
mineralization by down-regulating gene expression. A putative model for vanadium 
action during ECM mineralization is presented in Figure 6. 
 
Table 1. Effects of vanadium on vertebrate bone-derived cell systems. 
 
Effects Mammalian Non-mammalian 
Cell line 
Name MC3T3-E1 UMR106 VSa13 
Origin Mouse 
calvaria 
Rat 
osteosarcoma 
Seabream 
vertebra 
Cell type Pre-
osteoblastic 
Differentiated 
osteoblast Chondrocyte-like 
Vanadate acute toxicity (1 mM during 4 h) 
 ↓↓ 
[54]
 ↓ 
[54]
 ↓ 
[52]
 
Phenotype 
Proliferation ↑ * [44,46,49,50,55,56] ↑ [44,49,50,55,56] ↑↑ **[52] 
ECM mineralization ↑↑↑ [50] NT ↓↓↓ [52] 
Protein content ↑↑ [44] ↑ [44] ↑↑↑ [UR] 
Cell differentiation 
ALP activity ↔ [50] ↓↓↓ [44,49,50,54,56] ↓↓↓ ** [UR] 
Type-I collagen 
synthesis ↑ * 
[50]
 ↑↑↑ * 
[50]
 NT 
Other activities 
Glucose consumption ↑↑ ** [44] ↑↑↑ ** [44,49,56] NT 
PTPase ↓↓↓ [46] ↓↓↓ [50] NT 
ERK activation ↑ * [50] ↑ * [49,50] NT 
* indicates insulin-like effect; ** indicates non-insulin-like effect; NT indicates not tested; UR 
indicates unpublished result 
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Figure 6. Vanadium putative regulation mechanisms for extracellular matrix (ECM) mineralization in 
VSa13 and MC3T3-E1 cells. ECMM indicates mineralized ECM; P indicates phosphorylation of ERK; V 
indicates vanadium; light grey arrows and dashed lines indicate vanadium putative effects in VSa13 cells; 
dark grey arrows and lines indicate PDGF effect in MC3T3-E1 cells; black dashed/dotted arrows indicate 
vanadium putative effects in MC3T3-E1 cells; dotted arrow indicates PI-3K/ras/MAPK pathway; below 
are represented micrographs of non-mineralized and mineralized VSa13 cells. 
 
5. CONCLUDING REMARKS 
 
This chapter presents a comprehensive collection of in vitro data regarding the 
effects of vanadium on bone metabolism in mammals. It also describes the recent work 
performed in fish bone-derived cells shown to respond to insulin, but also to be finely 
regulated by vanadate. In these cells, like in mammalian bone-derived cell lines, 
vanadate behaves as a growth factor, stimulating VSa13 cell proliferation through an 
insulin-independent mechanism. On the contrary, ECM mineralization of VSa13 cells is 
negatively regulated by insulin and vanadium, with a stronger inhibition resulting from 
the combination of both treatments. Based on previous studies, it is suggested that this 
effect may be mediated through activation of ERK pathway and consequent down-
regulation of mineralization. However, in order to confirm specific involvement of this 
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pathway further investigation will be necessary. Preliminary results in VSa13 cells have 
so far indicated (1) the involvement of MAPK pathways in the vanadate effects on cell 
proliferation through a non-insulin related mechanism, and (2) the vanadate-dependent 
inhibition of cell differentiation through an effect on ALP activity. In general, it is 
important to notice that full characterization of vanadium effects in bone-derived 
systems will require further investigation. Additional suggested studies include analysis 
of: a) combined action of vanadium and other growth factors (e.g. IGF1, TGF-β); 
b) general gene expression during vanadium treatments (using microarray technology); 
c) specific bone-related gene expression; d) specific bone-related protein synthesis. The 
development of non-mammalian in vitro systems is likely to bring new insights on 
vanadium mechanisms of action in bone. 
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